PT - JOURNAL ARTICLE AU - Zheng, Xiaoli AU - Liu, Yanqing AU - Yu, Qinqin AU - Wang, Hua AU - Tan, Fuqing AU - Zhu, Qianying AU - Yuan, Lingmin AU - Jiang, Huidi AU - Zeng, Su AU - Yu, Lushan TI - Response to Comment on “Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin” AID - 10.1126/scitranslmed.aam6298 DP - 2017 May 24 TA - Science Translational Medicine PG - eaam6298 VI - 9 IP - 391 4099 - http://stm.sciencemag.org/content/9/391/eaam6298.short 4100 - http://stm.sciencemag.org/content/9/391/eaam6298.full AB - OCT2 plays a key role in synergy between decitabine and oxaliplatin in renal cell carcinoma cell lines.